1. Home
  2. DTIL vs SABS Comparison

DTIL vs SABS Comparison

Compare DTIL & SABS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precision BioSciences Inc.

DTIL

Precision BioSciences Inc.

N/A

Current Price

$7.35

Market Cap

362.6M

Sector

Health Care

ML Signal

N/A

Logo SAB Biotherapeutics Inc.

SABS

SAB Biotherapeutics Inc.

N/A

Current Price

$2.85

Market Cap

293.9M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DTIL
SABS
Founded
2006
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
362.6M
293.9M
IPO Year
2019
2020

Fundamental Metrics

Financial Performance
Metric
DTIL
SABS
Price
$7.35
$2.85
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
11
Target Price
★ $29.40
$11.64
AVG Volume (30 Days)
402.8K
★ 684.9K
Earning Date
11-03-2026
11-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 78.53
EPS
N/A
★ N/A
Revenue
★ $1,070,000,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$3.53
$2.44
52 Week High
$11.29
$5.15

Technical Indicators

Market Signals
Indicator
DTIL
SABS
Relative Strength Index (RSI) 48.99 43.62
Support Level $6.12 $2.44
Resistance Level $7.80 $4.03
Average True Range (ATR) 0.93 0.26
MACD -0.22 -0.02
Stochastic Oscillator 17.63 37.58

Price Performance

Historical Comparison
DTIL
SABS

About DTIL Precision BioSciences Inc.

Precision BioSciences Inc clinical stage gene editing company utilizing its proprietary ARCUS platform to concurrently develop two clinical-stage in vivo gene editing therapies. The ARCUS platform is used to develop in vivo gene editing therapies for sophisticated gene edits, including gene insertion (inserting DNA into gene to cause expression/add function), elimination (removing a genome, e.g. viral DNA), and excision (removing a large portion of a defective gene by delivering two ARCUS nucleases in a single adeno-associated virus ("AAV")).

About SABS SAB Biotherapeutics Inc.

SAB Biotherapeutics Inc is a clinical-stage biopharmaceutical company focused on developing multi-specific, high-potency, human immunoglobulin G (hIgG) to treat and prevent immune and autoimmune disorders. The company's lead product candidate, SAB-142, targets autoimmune Type 1 Diabetes (T1D) with a disease-modifying therapeutic approach that aims to change the T1D treatment paradigm by delaying onset and potentially preventing disease progression of Stage 3 T1D patients. It is focused on developing product candidates for disease targets where a differentiated approach has the greatest potential to be either first-in-class against novel targets against complex targets to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders.

Share on Social Networks: